AbbVie Inc. (NYSE:ABBV) is listed among the 15 Best DRIP Stocks to Own Right Now. Piper Sandler raised AbbVie’s price target to $289 and maintained an Overweight rating, citing strong long-term expectations for Skyrizi starting in 2026 and improved forecasts for key products in AbbVie’s Neuroscience division.

In the third quarter of 2024, AbbVie’s immunology segment reported robust earnings of $7.89 billion, with global sales of Skyrizi rising 46.8% to $4.71 billion. Rinvoq revenues climbed 35.3% to $2.18 billion, while Humira revenues fell 55.4% to $993 million due to biologic similar competition. Total company revenue reached $15.7 billion, up 9.1% year-over-year.

AbbVie Inc. (NYSE:ABBV) is a research-driven biopharmaceutical company focused on discovering, developing, manufacturing, and marketing innovative medicines and therapies.

While AbbVie has investment potential, some AI stocks may offer greater upside potential with less downside risk. Consider exploring undervalued AI stocks that benefit from current economic trends.

Read more at Yahoo Finance: Piper Sandler Raises AbbVie (ABBV) Price Target to $289, Maintains Overweight Rating